Company Overview and News
Market Update: The market held on to morning gains, with the Sensex rising around 150 points while the Nifty Midcap index extended rally, rising nearly 1.5 percent.
519588 PWQFY PANAMAPET 500325 BHUSANSTL UBL 532439 TCHQY ASIANPAINT 532321 PIDILITIND PDLTY 500850 BJJQY MS 500570 524820 500055 500331 JMFINANCIL SNDMY RLNIY GE 534690 515030 532827 UNITDSPR 531978 JETAIRWAYS 532945 YYBKY 530005 532432 BAJAJFINSV VED 500180 COALINDIA GOLDINFRA 500820 GOODYEAR IDBI PNCINFRA 514034 532899 532810 TTNQY 533477 532540 ZUARIGLOB 512529 RIGD INFRATEL INDHOTEL TATAMOTORS 500034 514043 SUNDARMFIN INDUSINDBK UBHOLDINGS 513599 532527 532648 UNBWY VTUWY CDLYY OBEROIRLTY HDB 500168 GNE KARURVYSYA EXCELINDUS TTM 523405 RICOAUTO 539150 PAGEIND 590003 HIMATSEIDE MS.PRE RKFORGE MS.PRF MS.PRG MS.PRA 532755 532478 532511 CADILAHC 532482 534816 JBFIND KSCL 500378 500252 CLNDY 500650 PGDQY ENKEIWHEL 520008 AMBIKCO 539302 LAXMIMACH TECHM BAJFINANCE MS.PRI TATASTEEL TATLY MS.PRK JINDALSAW UQNTY TCS 534809 PCJEWELLER 507458 500780 WABAG HINDCOPPER SHRIRAMEPC BHRYY MONTECARLO RELIANCE ASAHIINDIA 532617 533273 532978 533278 538836 GRANULES 500470 532187 HDFCBANK SEQUENT INDIACEM 590071 YESBANK GEC 500116 533269 POWERMECH PFC DFM OBZIY TTST LAKSHVILAS EXCELCROP
Paraffin Oil Market 2018 Industry and forecast to 2023 report analyzed the world's main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, analysis, size, share, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...